Abstract
A few open studies on small groups of patients have reported the efficacy of oral vitamin D3 in the treatment of psoriasis. To further characterize the therapeutic potential of this agent a placebo-controlled double-blind study was undertaken on a larger group of patients. Vitamin D3 (the active 1-α-hydroxy form) 1 μg/day and a placebo in a similar presentation were given in coded vials to 50 patients. Slight improvement was observed in 9 (45%) patients receiving vitamin D3 and 8 (38%) patients receiving placebo showed similar improvement, indicating that this regimen is not effective in the treatment of moderate to severe psoriasis.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
